K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease
Latest Information Update: 03 Oct 2021
At a glance
- Drugs K1 70 (Primary) ; K1 70 (Primary)
- Indications Graves' disease
- Focus Adverse reactions; First in man
- Sponsors AV7
- 18 May 2021 Status changed from recruiting to completed.
- 12 Dec 2017 Planned End Date changed from 1 Apr 2017 to 1 Feb 2020.
- 12 Dec 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2020.